Fluidigm Corporation Commercial Tutorial

Immune monitoring studies, especially in the age of COVID-19 disease, require cytometry assays that:

• are quick to implement with an easy workflow;
• have fixation embedded early in sample processing;
• are high parameter to ensure the most information possible per cell;
• have a streamlined, reproducible and unbiased data analysis pipeline; and
• have proven reproducibility when performed at distant sites.

The Maxpar® Direct™ Immune Profiling System designed for use on Helios™, a CyTOF system, meets all these criteria. Frederik De Smet will present how the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar® Pathsetter™ software are being used in the COvid-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) to gain an in-depth characterization of the dynamic host immune response to SARS-CoV-2. Noah Saederup will provide background information on the Maxpar Direct family of products, their unique benefits for clinical research studies and data from a multi-site study using the Maxpar Direct Immune Profiling System.